Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation
Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R
Record ID 32016000944
English
Authors' objectives:
To systematically review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect,® Novartis Pharmaceuticals) and rabbit antihuman thymocyte immunoglobulin (Thymoglobuline,® Sanofi) as induction therapy and immediate-release tacrolimus [Adoport® (Sandoz); Capexion® (Mylan); Modigraf® (Astellas Pharma); Perixis® (Accord Healthcare); Prograf® (Astellas Pharma); Tacni® (Teva); Vivadex® (Dexcel Pharma)], prolonged-release tacrolimus (Advagraf,® Astellas Pharma); belatacept (BEL) (Nulojix,® Bristol-Myers Squibb), mycophenolate mofetil (MMF) [Arzip® (Zentiva), CellCept® (Roche Products), Myfenax® (Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy's Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium, sirolimus (Rapamune,® Pfizer) and everolimus (Certican,® Novartis Pharmaceuticals) as maintenance therapy in children and adolescents undergoing renal transplantation.
Authors' recommendations:
Tacrolimus (TAC) is likely to be cost-effective (vs. CSA, in combination with AZA) at £20,000–30,000 per QALY. Analysis based on one RCT found BAS to be dominant, but analysis based on another RCT found BAS to be dominated. BAS plus TAC and AZA was predicted to be cost-effective at £20,000–30,000 per QALY when all regimens were compared using extrapolated adult evidence. High-quality primary effectiveness research is needed. The UK Renal Registry could form the basis for a prospective primary study.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.journalslibrary.nihr.ac.uk/hta/hta20610/#/abstract
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Adolescent
- Child
- Cost-Benefit Analysis
- Immunosuppression Therapy
- Immunosuppressive Agents
- Kidney Transplantation
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.